Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.

[1]  D. Gregory,et al.  Infection of mouse liver by human adenovirus type 5. , 1978, The Journal of general virology.

[2]  P. Sharp,et al.  Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs , 1979, Cell.

[3]  N. Jones,et al.  An adenovirus type 5 early gene function regulates expression of other early viral genes. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Berk Aj.  Functions of adenovirus E1A. , 1986 .

[5]  A. Berk,et al.  Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. , 1987, Virology.

[6]  J. Nevins,et al.  The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation , 1989, Journal of virology.

[7]  N. Dyson,et al.  Cellular proteins that are targetted by DNA tumor viruses for transformation. , 1989, Princess Takamatsu symposia.

[8]  E. Harlow,et al.  Cellular targets for transformation by the adenovirus E1A proteins , 1989, Cell.

[9]  J. Nevins,et al.  An adenovirus E4 gene product trans-activates E2 transcription and stimulates stable E2F binding through a direct association with E2F. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Nevins,et al.  Activation of the E2F transcription factor in adenovirus-infected cells involves E1A-dependent stimulation of DNA-binding activity and induction of cooperative binding mediated by an E4 gene product , 1990, Journal of virology.

[11]  P. Branton,et al.  Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Nevins,et al.  Genetic analysis of the adenovirus E4 6/7 trans activator: interaction with E2F and induction of a stable DNA-protein complex are critical for activity , 1991, Journal of virology.

[13]  E. Moran,et al.  E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products , 1991, Molecular and cellular biology.

[14]  A. Berk,et al.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein , 1992, Nature.

[15]  N. Dyson,et al.  Adenovirus E1A makes two distinct contacts with the retinoblastoma protein , 1992, Journal of virology.

[16]  T. Shenk,et al.  Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1 , 1992, Journal of virology.

[17]  J. Howe,et al.  Effects of Ad5 E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. , 1992, Virology.

[18]  T. Shenk,et al.  Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription , 1993, Journal of Virology.

[19]  K. Helin,et al.  Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes , 1993, Molecular and cellular biology.

[20]  P. Yaciuk,et al.  Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth , 1993, Journal of virology.

[21]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[22]  S. Lowe,et al.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. , 1993, Genes & development.

[23]  E. Moran.  DNA tumor virus transforming proteins and the cell cycle. , 1993, Current opinion in genetics & development.

[24]  Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. , 1994, Genes & development.

[25]  P. Hearing,et al.  Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1 , 1994, Journal of virology.

[26]  K. Helin,et al.  Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6/7) protein , 1994, Journal of virology.

[27]  J. Nevins,et al.  Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. , 1994, Genes & development.

[28]  P. Hearing,et al.  The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex , 1994, Molecular and cellular biology.

[29]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Bayley,et al.  Adenovirus e1a proteins and transformation (review). , 1994, International journal of oncology.

[31]  R. Martuza,et al.  Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. , 1994, Cancer research.

[32]  P. Branton,et al.  Phosphorylation at the carboxy terminus of the 55-kilodalton adenovirus type 5 E1B protein regulates transforming activity , 1994, Journal of virology.

[33]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Nevins,et al.  Interacting domains of E2F1, DP1, and the adenovirus E4 protein , 1994, Journal of virology.

[35]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[36]  E. White.  Regulation of p53-dependent apoptosis by E1A and E1B. , 1995, Current topics in microbiology and immunology.

[37]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[38]  W. Sellers,et al.  Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter , 1994, Molecular and cellular biology.

[39]  N. Horikoshi,et al.  Oncogenic potential of the adenovirus E4orf6 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[41]  R N Rao.  Targets for cancer therapy in the cell cycle pathway. , 1996, Current opinion in oncology.

[42]  P. Branton,et al.  Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells , 1997, Journal of virology.

[43]  P. Wen,et al.  Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector , 1997, Nature Medicine.

[44]  J. Bartek,et al.  The retinoblastoma protein pathway in cell cycle control and cancer. , 1997, Experimental cell research.

[45]  A. Jacobs,et al.  Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. , 1997, Human gene therapy.

[46]  N. Ahn,et al.  Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4 , 1997, Journal of virology.

[47]  T. Dobner,et al.  The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Harper,et al.  S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation , 1997, Current Biology.

[49]  P. Branton,et al.  Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5 , 1997, Journal of virology.

[50]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[51]  D. Johnson,et al.  Role of E2F in cell cycle control and cancer. , 1998, Frontiers in bioscience : a journal and virtual library.

[52]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[53]  A. Jochemsen,et al.  The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells , 1998, Oncogene.

[54]  K. Helin,et al.  Regulation of cell proliferation by the E2F transcription factors. , 1998, Current opinion in genetics & development.

[55]  C. Larminie,et al.  Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein , 1998, Journal of Molecular Medicine.

[56]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[57]  R. Chung,et al.  B-myb Promoter Retargeting of Herpes Simplex Virus γ34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells , 1999, Journal of Virology.

[58]  A. Fattaey,et al.  CDK inhibition and cancer therapy. , 1999, Current opinion in genetics & development.

[59]  Y. Chiang,et al.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.

[60]  Y. Chen,et al.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. , 1999, Cancer research.

[61]  D. Kirn,et al.  Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. , 1999, Cancer research.

[62]  D. Yu,et al.  Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. , 1999, Cancer research.

[63]  K. Helin,et al.  The E2F transcription factors: key regulators of cell proliferation. , 2000, Biochimica et biophysica acta.

[64]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[65]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[66]  C. Sherr.  The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[67]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[68]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[69]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[70]  R. White,et al.  Survey and summary: transcription by RNA polymerases I and III. , 2000, Nucleic acids research.

[71]  Induction of the Cellular E2F-1 Promoter by the Adenovirus E4-6/7 Protein , 2000, Journal of Virology.

[72]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.

[73]  M. Clarke,et al.  A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. , 2000, Human gene therapy.

[74]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[75]  D. Brough,et al.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. , 2000, The Journal of clinical investigation.

[76]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[77]  L. Johnson,et al.  Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region , 2001, Gene Therapy.

[78]  T. Pawlik,et al.  Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. , 2001, Cancer research.

[79]  F. McCormick,et al.  Cancer gene therapy: fringe or cutting edge? , 2001, Nature Reviews Cancer.

[80]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  T. Hermiston,et al.  Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region , 2001, Gene Therapy.

[82]  A. Fattaey,et al.  Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein , 2001, Journal of Virology.

[83]  K. Uematsu,et al.  p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53 , 2001 .

[84]  R. Iggo,et al.  Replicating Adenoviruses That Target Tumors with Constitutive Activation of the wnt Signaling Pathway , 2001, Journal of Virology.

[85]  G. Demers,et al.  Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy , 2001, Nature Biotechnology.

[86]  W. Wold,et al.  Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy , 2001, Journal of Virology.

[87]  D. Kirn.  Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? , 2001, Gene Therapy.

[88]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[89]  R. Iggo,et al.  Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway , 2002, Gene Therapy.